Apatinib mesylate is a small molecule vascular endothelial growth factor receptor 2 (VEGFR-2) tyrosine kinase inhibitor that blocks signal transduction by binding of vascular endothelial growth factor (VEGF) to its receptor, potently inhibits tumor angiogenesis, and plays an anti-tumor therapeutic role.[3,4]. The gene discussed is VEGFA; the disease is neoplasm.